Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Core Insights - Solid Biosciences Inc. is a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases [3] - The company will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026, at 10:30 AM ET [1] Company Overview - Solid Biosciences is advancing a portfolio of gene therapy candidates targeting rare diseases, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich's ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for TNNT2-mediated dilated cardiomyopathy [3] - The company is also developing innovative libraries of genetic regulators and technologies to enhance gene therapy delivery across industries [3] - Founded by individuals affected by Duchenne, the company's mission is to improve the daily lives of patients with rare diseases [3]